

Robert Sidonio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6945826/publications.pdf>

Version: 2024-02-01

113
papers

1,985
citations

257101

24
h-index

288905

40
g-index

113
all docs

113
docs citations

113
times ranked

1729
citing authors

#	ARTICLE	IF	CITATIONS
1	ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. <i>Blood Advances</i> , 2021, 5, 280-300.	2.5	246
2	A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. <i>Blood</i> , 2019, 134, 2127-2138.	0.6	241
3	Rise in Late Onset Vitamin K Deficiency Bleeding in Young Infants Because of Omission or Refusal of Prophylaxis at Birth. <i>Pediatric Neurology</i> , 2014, 50, 564-568.	1.0	105
4	The Use of an Extracorporeal Membrane Oxygenation Anticoagulation Laboratory Protocol Is Associated With Decreased Blood Product Use, Decreased Hemorrhagic Complications, and Increased Circuit Life*. <i>Pediatric Critical Care Medicine</i> , 2015, 16, 66-74.	0.2	105
5	A cross-sectional study of bleeding phenotype in haemophilia A carriers. <i>British Journal of Haematology</i> , 2015, 170, 223-228.	1.2	75
6	Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis. <i>Haemophilia</i> , 2019, 25, 789-796.	1.0	59
7	A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1883-1887.	1.9	59
8	Novel therapeutics for hemophilia and other bleeding disorders. <i>Blood</i> , 2018, 132, 23-30.	0.6	46
9	Females with FVIII and FIX deficiency have reduced joint range of motion. <i>American Journal of Hematology</i> , 2014, 89, 831-836.	2.0	43
10	Discussing investigational AAV gene therapy with hemophilia patients: A guide. <i>Blood Reviews</i> , 2021, 47, 100759.	2.8	40
11	Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. <i>Journal of Pediatric Surgery</i> , 2016, 51, 122-127.	0.8	39
12	HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors. <i>Blood</i> , 2017, 130, 85-85.	0.6	38
13	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 129.	3.8	37
14	Proteinase expression during differentiation of human osteoclasts in vitro. <i>Journal of Cellular Biochemistry</i> , 2000, 78, 627-637.	1.2	35
15	Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1333-1337.	0.8	34
16	Clinical outcomes of splenectomy in children: Report of the splenectomy in congenital hemolytic anemia registry. <i>American Journal of Hematology</i> , 2015, 90, 187-192.	2.0	33
17	An international survey to inform priorities for new guidelines on von Willebrand disease. <i>Haemophilia</i> , 2020, 26, 106-116.	1.0	32
18	Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia A with Inhibitors: Results from the HAVEN 2 Study. <i>Blood</i> , 2018, 132, 632-632.	0.6	31

#	ARTICLE	IF	CITATIONS
19	Impact of hemophilia B on quality of life in affected men, women, and caregiversâ€”Assessment of patientâ€”reported outcomes in the Bâ€”HERO study. <i>European Journal of Haematology</i> , 2018, 100, 592-602.	1.1	30
20	Haemophilia A carriers experience reduced healthâ€”related quality of life. <i>Haemophilia</i> , 2015, 21, 761-765.	1.0	29
21	Haemophilia A carriers demonstrate pathological and radiological evidence of structural joint changes. <i>Haemophilia</i> , 2014, 20, e426-9.	1.0	28
22	Both Hemophilia Health Care Providers and Hemophilia A Carriers Report That Carriers Have Excessive Bleeding. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, e224-e230.	0.3	25
23	Management of <sc>US</sc> men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (Bâ€”HERO study). <i>European Journal of Haematology</i> , 2017, 98, 5-17.	1.1	25
24	The impact of age and <i><sc>CYP</sc>2C9</i> and <i><sc>VKORC</sc>1</i> variants on stable warfarin dose in the paediatric population. <i>British Journal of Haematology</i> , 2014, 165, 832-835.	1.2	24
25	Aberrant splicing contributes to severe α -spectrinâ€”linked congenital hemolytic anemia. <i>Journal of Clinical Investigation</i> , 2019, 129, 2878-2887.	3.9	24
26	Impact of diagnosis of von Willebrand disease on patient outcomes: Analysis of medical insurance claims data. <i>Haemophilia</i> , 2017, 23, 743-749.	1.0	22
27	The impact of extended halfâ€”life factor concentrates on prophylaxis for severe hemophilia in the United States. <i>American Journal of Hematology</i> , 2020, 95, 960-965.	2.0	19
28	Spontaneous bleeding and poor bleeding response with extended halfâ€”life factor IX products: A survey of select US haemophilia treatment centres. <i>Haemophilia</i> , 2020, 26, e128-e129.	1.0	19
29	The spectrum and severity of bleeding in adolescents with low von Willebrand factorâ€”associated heavy menstrual bleeding. <i>Blood Advances</i> , 2020, 4, 3209-3216.	2.5	17
30	Management of VWD. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 536-541.	0.9	16
31	Healthâ€”related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitorsâ€”Results from the HAVEN 2 study. <i>Haemophilia</i> , 2020, 26, 1009-1018.	1.0	16
32	Relevance of Abusive Head Trauma to Intracranial Hemorrhages and Bleeding Disorders. <i>Pediatrics</i> , 2018, 141, e20173485.	1.0	15
33	The spectrum of bleeding in women and girls with haemophilia B. <i>Haemophilia</i> , 2018, 24, 180-185.	1.0	15
34	A decreased and less sustained desmopressin response in hemophilia A carriers contributes to bleeding. <i>Blood Advances</i> , 2018, 2, 2629-2636.	2.5	15
35	Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events. <i>Journal of Medical Economics</i> , 2019, 22, 1328-1337.	1.0	15
36	Laboratory misdiagnosis of von Willebrand disease in <sc>postâ€”menarchal</sc> females: A <sc>multiâ€”center</sc> study. <i>American Journal of Hematology</i> , 2020, 95, 1022-1029.	2.0	15

#	ARTICLE	IF	CITATIONS
37	Elevated von Willebrand factor levels during heavy menstrual bleeding episodes limit the diagnostic utility for von Willebrand disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12513.	1.0	15
38	Women and girls with haemophilia and bleeding tendencies: Outcomes related to menstruation, pregnancy, surgery and other bleeding episodes from a retrospective chart review. <i>Haemophilia</i> , 2021, 27, 293-304.	1.0	15
39	Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States. <i>Haemophilia</i> , 2021, 27, 1037-1044.	1.0	14
40	New developments in pediatric venous thromboembolism and anticoagulation, including the target-specific oral anticoagulants. <i>Current Opinion in Pediatrics</i> , 2015, 27, 18-25.	1.0	13
41	Emicizumab in tolerized patients with hemophilia A with inhibitors: A single-institution pediatric cohort assessing inhibitor status. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 342-348.	1.0	13
42	Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States. <i>Haemophilia</i> , 2021, 27, 445-453.	1.0	13
43	International consensus recommendations on the management of people with haemophilia B. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210852.	1.1	13
44	A two-center retrospective review of the hematologic evaluation and laboratory abnormalities in suspected victims of non-accidental injury. <i>Child Abuse and Neglect</i> , 2014, 38, 1794-1800.	1.3	12
45	A Cross-Sectional Study of Women and Girls with Congenital Bleeding Disorders: The American Thrombosis and Hemostasis Network Cohort. <i>Journal of Women's Health</i> , 2020, 29, 670-676.	1.5	12
46	<p>Potential Undiagnosed VWD Or Other Mucocutaneous Bleeding Disorder Cases Estimated From Private Medical Insurance Claims</p>. <i>Journal of Blood Medicine</i> , 2020, Volume 11, 1-11.	0.7	11
47	Idiopathic Myelofibrosis in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, 559-565.	0.3	10
48	Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States. <i>Journal of Medical Economics</i> , 2018, 21, 762-769.	1.0	10
49	Health issues in women and girls affected by haemophilia with a focus on nomenclature, heavy menstrual bleeding, and musculoskeletal issues. <i>Haemophilia</i> , 2022, 28, 18-25.	1.0	10
50	Predictors of von Willebrand disease in children. <i>Pediatric Blood and Cancer</i> , 2012, 58, 736-740.	0.8	8
51	Reliability and validity of patient-reported outcome instruments in US adults with hemophilia B and caregivers in the B“HERO” study. <i>European Journal of Haematology</i> , 2018, 101, 781-790.	1.1	7
52	Substitution therapy. <i>Haemophilia</i> , 2021, 27, 53-59.	1.0	7
53	The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. <i>Haemophilia</i> , 2021, 27, 921-931.	1.0	7
54	Cost-Utility Analysis of Von Willebrand Disease Screening in Adolescents with Menorrhagia.. <i>Blood</i> , 2009, 114, 2476-2476.	0.6	7

#	ARTICLE	IF	CITATIONS
55	Hemophilia B (Factor IX Deficiency). <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1143-1155.	0.9	6
56	Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy. <i>Blood Advances</i> , 2021, 5, 5023-5031.	2.5	6
57	Design of an international investigator-initiated study on MODern Treatment of Inhibitor-positive pATiEnts with haemophilia A (MOTIVATE). <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110324.	1.1	6
58	Spontaneous Bleeding and Poor Bleeding Response with Extended Half-Life Factor IX Products: A Survey of Select US and Canadian Hemophilia Treatment Centers. <i>Blood</i> , 2019, 134, 2407-2407.	0.6	6
59	Managing Severe Hemophilia A in Children: Pharmacotherapeutic Options. <i>Pediatric Health, Medicine and Therapeutics</i> , 2022, Volume 13, 27-35.	0.7	6
60	Screening for von Willebrand disease in children: a case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1086-1089.	1.9	5
61	Incidence and Timing of Thrombosis After the Norwood Procedure in the Single-Ventricle Reconstruction Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e015882.	1.6	5
62	Characterizing female patients with haemophilia A: Administrative claims analysis and medical chart review. <i>Haemophilia</i> , 2020, 26, 520-528.	1.0	5
63	von Willebrand disease: proposing definitions for future research. <i>Blood Advances</i> , 2021, 5, 565-569.	2.5	5
64	Bleeding patterns in patients before and after diagnosis of von Willebrand disease: Analysis of a US medical claims database. <i>Haemophilia</i> , 2021, , .	1.0	5
65	Bone health in haemophilia carriers and persons with von Willebrand disease: A large database analysis. <i>Haemophilia</i> , 2022, 28, 671-678.	1.0	5
66	Three Cost-utility Analyses of Screening for Intracranial Hemorrhage in Neonates With Hemophilia. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, 474-479.	0.3	4
67	Acquired Hypofibrinogenemia Before Asparaginase Exposure During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia: A Report of 2 Cases and Review of the Literature. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, e470-e472.	0.3	4
68	A cross-sectional study of non-attendance among patients at a US hemophilia treatment center 2010-2014. <i>Haemophilia</i> , 2018, 24, 902-910.	1.0	4
69	TFPI blockade: removing coagulation's brakes. <i>Blood</i> , 2019, 134, 1885-1887.	0.6	4
70	Assessing the Safety of Various VWF Regimens in Patients with Clinically Severe VWD: A Natural History Study. <i>Blood</i> , 2019, 134, 1132-1132.	0.6	4
71	Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations. <i>Blood Advances</i> , 2022, 6, 420-428.	2.5	4
72	von Willebrand disease Outreach into Integrated Care Education (VOICE): a call to action. <i>Haemophilia</i> , 2017, 23, e370-e373.	1.0	3

#	ARTICLE	IF	CITATIONS
73	<p>Correlations between patient-reported outcomes and self-reported characteristics in adults with hemophilia B and caregivers of children with hemophilia B: analysis of the B-HERO-S study</p>. Patient Related Outcome Measures, 2019, Volume 10, 299-314.	0.7	3
74	Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia, 2021, 27, 211-220.	1.0	3
75	Severe Bleeding Events in Hemophilia ð Patients Receiving Emicizumab Prophylaxis. Blood, 2019, 134, 1126-1126.	0.6	3
76	Evaluating the psychosocial impact of hemophilia B: The Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (Bâ€HERO</sc>â€) study. European Journal of Haematology, 2017, 98, 3-4.	1.1	2
77	Successful Perioperative Management of Orthotopic Cardiac Transplantation in a Pediatric Patient With Concurrent Congenital von Willebrand Disease and Acquired von Willebrand Syndrome Using Recombinant von Willebrand Factor. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 724-727.	0.6	2
78	The Atlanta Protocol: Immune Tolerance Induction in Pediatric Patients with Hemophilia a and Inhibitors on Emicizumab. Blood, 2018, 132, 634-634.	0.6	2
79	Model of the Impact of Delayed Inhibitor Development on Cumulative Breakthrough Bleeds and Costs in Persons with Hemophilia A Receiving Emicizumab Prophylaxis. Blood, 2018, 132, 4710-4710.	0.6	2
80	Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia a: Interim Results from an Open-Label Multicenter Clinical Trial. Blood, 2021, 138, 3184-3184.	0.6	2
81	Depression and Anxiety in Persons with Von Willebrand Disease. Blood, 2021, 138, 4052-4052.	0.6	2
82	Healthcare Utilization and Health Related Quality of Life in Persons with Von Willebrand Disease. Blood, 2020, 136, 3-4.	0.6	2
83	Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 518-527.	0.5	2
84	COVID-19 Cliff Notes: A COVID-19 Multidisciplinary Care Compendium. Transplantation and Cellular Therapy, 2021, 27, 474.e1-474.e3.	0.6	1
85	Plasma factor IX: The tip of the iceberg?. Haemophilia, 2021, 27, 329-331.	1.0	1
86	Prospective Diagnosis of VWD in a Large Cohort of Patients with Bleeding Symptoms through the Zimmerman Program. Blood, 2018, 132, 979-979.	0.6	1
87	Real World Use of Extended Half-Life Products and the Impact on Bleeding Events and Joint Health in the United States. Blood, 2018, 132, 1195-1195.	0.6	1
88	Thrombotic Outcomes Following Hormonal Treatment of Heavy Menstrual Bleeding in Pediatric Patients Taking Anticoagulation. Blood, 2019, 134, 2179-2179.	0.6	1
89	Impact of Mild to Severe Hemophilia B on Quality of Life Including Pain and Functional Abilities in Affected Men/Women and Caregivers of Affected Boys/Girls: Analysis of Patient Reported Outcomes in the Bridging Hemophilia B Experiences Results and Opportunities into Solutions (B-HERO-S) Study. Blood, 2016, 128, 251-251.	0.6	1
90	Discordance in Provider Practice Patterns and Hemophilia A Carrier Health Care Preferences. Blood, 2012, 120, 3385-3385.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial. Blood, 2019, 134, 1130-1130.	0.6	1
92	Lack of Inhibitor Development in the American Thrombosis and Hemostasis Network (ATHN)-2 Factor Switching Study: Preliminary Report of Primary Outcome. Blood, 2019, 134, 1114-1114.	0.6	1
93	Predictors of Von Willebrand Disease In Children: A Case-Control Study. Blood, 2010, 116, 712-712.	0.6	0
94	Factor VIII Intron 22 Inversion Screening of Newborn Males for Hemophilia A: A Cost-Effectiveness Study. Blood, 2010, 116, 734-734.	0.6	0
95	Retrospective Review of Hematologic Evaluation in Children with Suspected Non-Accidental Injury, A First Step towards Evidence Based Guidelines.. Blood, 2012, 120, 2231-2231.	0.6	0
96	Females With FVIII Deficiency Have Reduced Mean Overall Joint Range Of Motion. Blood, 2013, 122, 3601-3601.	0.6	0
97	One-Stage FVIII Activity Is Inversely Correlated with Heavy Menstrual Bleeding in Hemophilia a Carriers. Blood, 2015, 126, 3542-3542.	0.6	0
98	Bleeding Severity and Health Care Utilization in Patients with Platelet Function Disorders. Blood, 2018, 132, 4994-4994.	0.6	0
99	Analysis of Bleeding and Treatment Patterns in Children and Adolescents before and after Von Willebrand Disease Diagnosis Using Data from a US Medical Claims Database. Blood, 2019, 134, 2117-2117.	0.6	0
100	The Discordance between Offsite to Onsite Testing for Von Willebrand Disease in Post-Menarchal Females: A Multi-Center Study. Blood, 2019, 134, 628-628.	0.6	0
101	Obtaining a Von Willebrand Evaluation at Time of Acute Heavy Menstrual Bleeding Presentation Leads to Overestimation of Von Willebrand Levels. Blood, 2019, 134, 627-627.	0.6	0
102	Clinical Study to Investigate the Efficacy and Safety of Wilate during Prophylaxis in Previously Treated Patients with Von Willebrand Disease (VWD). Blood, 2019, 134, 4931-4931.	0.6	0
103	Hemophilia Carriers. , 2020, , 43-50.		0
104	Prevalence of Acute and Chronic Migraine Among Patients with Von Willebrand Disease. Blood, 2021, 138, 4245-4245.	0.6	0
105	A Multi-Institution Retrospective Study to Assess Bleeding Phenotype Among Patients with Platelet Function Disorders. Blood, 2021, 138, 3033-3033.	0.6	0
106	Assessment of TRM-201 (Rofecoxib) Efficacy and Safety for Chronic Pain in Hemophilic Arthropathy: The Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy (RESET-HA), a Randomized, Double-Blind Placebo-Controlled Phase III Clinical Trial. Blood, 2021, 138, 4243-4243.	0.6	0
107	Bleeding in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD). Blood, 2021, 138, 3183-3183.	0.6	0
108	Rurioctocog Alfa Pegol Use in Immune Tolerance Induction: Interim Results from an Open-Label Multicenter Clinical Trial in Previously Untreated Patients with Severe Hemophilia a. Blood, 2021, 138, 3185-3185.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Surgery-Associated Bleeding Risk in Patients with Platelet Function Disorders - a Cross Sectional Study with the American Thrombosis and Hemostasis Network Dataset (ATHNdataset). Blood, 2021, 138, 180-180.	0.6	0
110	Real-World Data of the Hemostatic Efficacy of Recombinant Human Factor VIIa Eptacog Beta for Acute Bleeding Events in Patients with Hemophilia a and B with Inhibitors. Blood, 2021, 138, 4246-4246.	0.6	0
111	PREDICT: A Multicenter, Prospective, Open-Label, Clinical Study Using a New Risk Score Approach to Assess the Most Appropriate Prophylaxis Regimen to Reach Favorable Outcomes in Hemophilia A, When Switching from Standard-Half-Life Products to Damoctocog Alfa Pegol. Blood, 2021, 138, 2115-2115.	0.6	0
112	OP031: The emotional experience of hemophilia heterozygote women: Average maternal guilt, effective coping strategies, and resilience within the hemophilia community. Genetics in Medicine, 2022, 24, S359-S360.	1.1	0
113	âœA New Hemophilia Carrier Nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTHâœ Reply to comment. Journal of Thrombosis and Haemostasis, 2022, 20, 1745-1746.	1.9	0